VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy

About the Cell-CT™ Platform

The automated Cell-CT™ platform, with 3-dimensional single cell Imaging and analysis capability, is the enabling technology which produces high-resolution 3D images of individual cells using a technique called optical computed tomography. This 3D optical CT platform breaks new ground in the field of quantitative cell analysis by its unique ability to compute the true 3D internal structure of cells based on molecular optical absorption densities. The Cell-CT platform produces high-resolution 3D images of individual cells and measures hundreds of critical disease indicators in each cell. Together with advanced artificial intelligence (AI) algorithms, these produce accurate cell classifications that aid in the early detection of disease. Additionally, the Cell-CT platform has the potential to deliver molecular and genetic biosignatures of disease longitudinally to compliment drug development in the biopharma services arena. Cells are not placed on slides, but rather, they are suspended in fluid (liquid biopsy) and injected through a micro-capillary tube that permits multiple viewing perspectives around 360°. The Cell-CT platform is a device under development and not currently cleared by the FDA.

Cautionary Note Regarding Forward-Looking Statements for VisionGate

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. These forward-looking statements are based on estimates, projections, beliefs and assumptions of the Company at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions  that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug and diagnostics development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.  VisionGate disclaims any intent or obligation to update these forward-looking statements.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release. 


i The Malignancy Associated Change Hypothesis Tested Through 3D Cellular Imaging, Poster #LB-175, Meyer, et. al., 2018 American Association for Cancer Research (AACR)

Attachment

Randall Mastrangelo
VisionGate, Inc.
602.368.2118 extension 1
mastrangelo@visiongate3d.com



« Previous Page 1 | 2             
Featured Video
Editorial
Jobs
Mechanical Test Engineer, Platforms Infrastructure for Google at Mountain View, California
Mechanical Manufacturing Engineering Manager for Google at Sunnyvale, California
Senior Principal Mechanical Engineer for General Dynamics Mission Systems at Canonsburg, Pennsylvania
Manufacturing Test Engineer for Google at Prague, Czechia, Czech Republic
Mechanical Engineer 3 for Lam Research at Fremont, California
Mechanical Engineer 2 for Lam Research at Fremont, California
Upcoming Events
Celebrate Manufacturing Excellence at Anaheim Convention Center Anaheim CA - Feb 4 - 6, 2025
3DEXPERIENCE World 2025 at George R. Brown Convention Center Houston TX - Feb 23 - 26, 2025
TIMTOS 2025 at Nangang Exhibition Center Hall 1 & 2 (TaiNEX 1 & 2) TWTC Hall Taipei Taiwan - Mar 3 - 8, 2025
Additive Manufacturing Forum 2025 at Estrel Convention Cente Berlin Germany - Mar 17 - 18, 2025



© 2024 Internet Business Systems, Inc.
670 Aberdeen Way, Milpitas, CA 95035
+1 (408) 882-6554 — Contact Us, or visit our other sites:
AECCafe - Architectural Design and Engineering EDACafe - Electronic Design Automation GISCafe - Geographical Information Services TechJobsCafe - Technical Jobs and Resumes ShareCG - Share Computer Graphic (CG) Animation, 3D Art and 3D Models
  Privacy PolicyAdvertise